Applications of Semaglutide for Various Diseases
DOI:
https://doi.org/10.62051/ccdpax22Keywords:
GLP-1 receptor agonist, semaglutide, obesity, diabetes, neurodegenerative diseases.Abstract
Semaglutide is a gluten-like peptide 1 (GLP-1) agonist which is responsible for improving blood sugar control and losing weight. It is clinically approved by the FDA for treatment of type 2 diabetes mellitus and is designed in subcutaneous or oral dosage form. Some other diseases share common conditions with obesity and diabetes such as a high blood sugar level and insulin resistance. These factors along with some neuron issues are responsible for neurodegenerative diseases. Obesity and diabetes are two common worldwide health issues. A number of trials have been conducted to estimate the prevalence and drug effects. Scientists also study related diseases such as Non-alcoholic fatty liver disease to verify the usefulness of treatments. Semaglutide is one of the drugs being measured whether has a potential effect on these diseases. Some pre-clinical studies have indicated its therapeutic potential in non-alcoholic steatohepatitis and neurodegenerative disorders. Semaglutide has proved to be effective in treating lots of disorders, especially diabetes and obesity. However, for other diseases, it still remains uncertain even if there are some studies already tested the effectiveness. Much more detailed and considerate studies should be conducted to verify the impact. Semaglutide, the GLP-1 receptor agonist, has shown a positive impact in treating different diseases. Researchers have tested hepatoprotective and neuroprotective activity in animal and human trials to get more reliable data. It turns out that semaglutide improves insulin resistance and reduces blood sugar levels. It also protects dopaminergic neurons and reduces aggregated α-synuclein which improves Parkinson’s disease and Alzheimer’s disease conditions.
Downloads
References
[1] Information on: https://www.who.int/news-room/fact-sheets/detail/diabetes
[2] D.H. Ryan, I. Lingvay, J. Deanfield, S. E. Kahn, E. Barros, B. Burguera, H. M. Colhoun, C. Cercato, D. Dicker, D. B. Horn, G. K. Hovingh, O. K. Jeppeses, A. Kokkinos, A. M. Lincoff, S. M. Meyhöfer, T. K. Oral, J. Plutzky, A. P. V. Beek, J. P. H. Wilding, R. F. Kushner, Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial, Nat Med 30(2024), 2049–2057.
[3] M. K. Mahapatra, M. Karuppasamy, B.M. Sahoo, Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review, Pharmaceutical Research, 39(2022), 1233–1248.
[4] Information on: https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/byetta/faq-20057955
[5] Information on: https://www.ncbi.nlm.nih.gov/books/NBK603723/#:~:text=Mechanism%20of%20Action&text=The%20mechanisms%20through%20which%20semaglutide,tract%2C%20pancreas%2C%20and%20brain.
[6] K. E. Miles, J. L. Kerr, Semaglutide for the Treatment of Type 2 Diabetes Mellitus, The Journal of pharmacy technology: jPT: official publication of the Association of Pharmacy Technicians, 34(2018), 281–289.
[7] V. Perkovic, K. R. Tuttle, P. Rossing, K. W. Mahaffey, J. F. E. Mann, G. Bakris, F. M. M. Baeres, T. Idorn, H. Bosch-Traberg, N. L. Lausvig, R. Pratley, FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes, The New England journal of medicine, 391(2024), 109–121.
[8] Information on: https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity#:~:text=New%20study%20released%20by%20the,to%2019%20years%20of%20age
[9] Information on: https://www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver-disease/symptoms-causes/syc-20354567
[10] V. W. Wong, M. Ekstedt, G. L. Wong, H. Hagström, Changing epidemiology, global trends and implications for outcomes of NAFLD, Journal of hepatology, 79(2023), 842–852.
[11] S. Bandyopadhyay, S. Das, S. S. Samajdar, S. R. Joshi, Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis, Diabetes & metabolic syndrome, 17(2023), 102849.
[12] A. M. Lincoff, K. Brown-Frandsen, H. M. Colhoun, J. Deanfield, S. S. Emerson, S. Esbjerg, S. Hardt-Lindberg, G. K. Hovingh, S. E. Kahn, R. F. Kushner, I. Lingvay, T. K. Oral, M. M. Michelsen, J. Plutzky, C. W. Tornøe, D. H. Ryan, SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, The New England journal of medicine, 389(2023), 2221–2232.
[14] Z. J. Wang, X. R. Li, S. F. Chai, W. R. Li, S. Li, M. Hou, J. L. Li, Y. C. Ye, H. Y. Cai, C. Hölscher, M. N. Wu, Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway, Neuropharmacology, 240(2023), 109716.
[15] L. Zhang, C. Li, Z. Zhang, Z. Zhang, Q. Q. Jin, L. Li, C. Hölscher, DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model, Parkinson's disease, 10(2022), 1428817
Downloads
Published
Conference Proceedings Volume
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







